Bayer advances pulmonary hypertension research
Will co-operate with Ludwig Boltzmann Institute for lung vascular research
Bayer HealthCare is entering into a new research alliance with the Ludwig Boltzmann Institute (LBI) for Lung Vascular Research in Austria to study treatments for respiratory illnesses such as pulmonary hypertension.
The Bayer-sponsored facility, based at the University of Graz, is owned by the Ludwig Boltzmann Gesellschaft.
Dr Helmut Haning, head of Global Innovation Sourcing at Bayer HealthCare, said the Ludwig Boltzmann Institute for Lung Vascular Research has bundled renowned expertise in the field of pulmonary hypertension, an area with considerable unmet medical need.
‘Pulmonary hypertension is also central to Bayer’s research and development activities, so the LBI for Lung Vascular Research is an attractive partner for us, with which we want to develop new treatment options for PH patients,’ he said.
The LBI studies the development of the blood vessels that carry blood through the lungs. A lung vascular dysfunction can result in pulmonary hypertension, a severe and life-threatening disease that can lead to heart failure and death.
Bayer Healthcare will also work with other partners including the medical device manufacturer NEBU-Tec and the Austrian Academy of Sciences.